Concepedia

Publication | Open Access

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

DOIFull Paper Access

69

Citations

23

References

2023

Year

Rahul Aggarwal, Stephanie Starzinski, Ivan de Kouchkovsky, Vadim S. Koshkin, Rohit Bose, Jonathan Chou, Arpita Desai, Daniel H. Kwon, Samuel Kaushal, Lauren Trihy,
The Lancet Oncology

Abstract

Prostate Cancer Foundation, National Cancer Institute, Novartis Pharmaceuticals, and Merck.

References

YearCitations

Page 1